[{"Assets_0_Q3_USD":444507000.0,"CommonStockSharesOutstanding_0_Q3_shares":144522000.0,"EarningsPerShareBasic_1_Q3_USD":-0.19,"EarningsPerShareBasic_3_Q3_USD":-0.55,"EarningsPerShareDiluted_1_Q3_USD":-0.19,"EarningsPerShareDiluted_3_Q3_USD":-0.55,"NetIncomeLoss_1_Q3_USD":-27850000.0,"NetIncomeLoss_3_Q3_USD":-78204000.0,"StockholdersEquity_0_Q3_USD":239738000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":143949000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":143396000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":143949000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":143396000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS INC","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20181106"}]